Literature DB >> 9303337

T cell activity and cytokine production in X-linked agammaglobulinemia: implications for vaccination strategies.

A Plebani1, M B Fischer, A Meini, M Duse, V Thon, M M Eibl.   

Abstract

In the 5 X-linked agammaglobulinemia (XLA) patients studied we show that memory T cells are present and that T lymphocytes proliferate normally to mitogens, monoclonal antibodies and, in particular, to recall antigens demonstrating normal in vivo T cell priming despite the absence of B cells. Furthermore, in vitro T cell activation in response to both T cell receptor-independent and T-cell receptor-dependent signals leads to a pattern of cytokine production characteristic of primed T cells and necessary for normal T cell function. These data are in good agreement with results obtained in gene-targeted mice and further support the concept that the absence of B cells does not impair induction of in vivo T cell memory and effector function which is generally considered to be of great importance in conferring protection against viral infections. Thus, while there is no risk of inducing infections in XLA patients by administering vaccines containing killed viruses or recombinant viral proteins, stimulation of T cell immunity by such vaccines may be of potential benefit particularly in the defense against infections with viruses such as the hepatitis B virus to which hypogammaglobulinemic patients are particularly exposed.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9303337     DOI: 10.1159/000237649

Source DB:  PubMed          Journal:  Int Arch Allergy Immunol        ISSN: 1018-2438            Impact factor:   2.749


  7 in total

1.  Importance of B cell co-stimulation in CD4(+) T cell differentiation: X-linked agammaglobulinaemia, a human model.

Authors:  H Martini; V Enright; M Perro; S Workman; J Birmelin; E Giorda; I Quinti; V Lougaris; M Baronio; K Warnatz; B Grimbacher
Journal:  Clin Exp Immunol       Date:  2011-04-13       Impact factor: 4.330

2.  X-linked agammaglobulinemia: ınvestigation of clinical and laboratory findings, novel gene mutations and prevention of ınfective complications in long-term follow-up.

Authors:  İlke Yıldırım; Ezgi Topyıldız; Raziye Burcu Güven Bilgin; Ayça Aykut; Asude Durmaz; Neslihan Edeer Karaca; Guzide Aksu; Necil Kutukculer
Journal:  Am J Clin Exp Immunol       Date:  2021-02-15

3.  High-throughput sequencing reveals an altered T cell repertoire in X-linked agammaglobulinemia.

Authors:  Manish Ramesh; Noa Simchoni; David Hamm; Charlotte Cunningham-Rundles
Journal:  Clin Immunol       Date:  2015-09-07       Impact factor: 3.969

4.  Dendritic and T cell response to influenza is normal in the patients with X-linked agammaglobulinemia.

Authors:  Yinping Liu; Yuet Wu; Kwok-Tai Lam; Pamela Pui-Wah Lee; Wenwei Tu; Yu-Lung Lau
Journal:  J Clin Immunol       Date:  2012-06       Impact factor: 8.317

Review 5.  Vaccine-Induced Severe Acute Respiratory Syndrome Coronavirus 2 Antibody Response and the Path to Accelerating Development (Determining a Correlate of Protection).

Authors:  Amy C Sherman; Michaël Desjardins; Lindsey R Baden
Journal:  Clin Lab Med       Date:  2021-11-03       Impact factor: 1.935

6.  SARS-CoV-2 T Cell Response in Severe and Fatal COVID-19 in Primary Antibody Deficiency Patients Without Specific Humoral Immunity.

Authors:  Sophie Steiner; Tatjana Schwarz; Victor M Corman; Laura Gebert; Malte C Kleinschmidt; Alexandra Wald; Sven Gläser; Jan M Kruse; Daniel Zickler; Alexander Peric; Christian Meisel; Tim Meyer; Olga L Staudacher; Kirsten Wittke; Claudia Kedor; Sandra Bauer; Nabeel Al Besher; Ulrich Kalus; Axel Pruß; Christian Drosten; Hans-Dieter Volk; Carmen Scheibenbogen; Leif G Hanitsch
Journal:  Front Immunol       Date:  2022-03-10       Impact factor: 7.561

Review 7.  T Cell Abnormalities in X-Linked Agammaglobulinaemia: an Updated Review.

Authors:  Sanchi Chawla; Ankur Kumar Jindal; Kanika Arora; Rahul Tyagi; Manpreet Dhaliwal; Amit Rawat
Journal:  Clin Rev Allergy Immunol       Date:  2022-06-16       Impact factor: 10.817

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.